ArticleEuropean journal of immunology2025
Booster Injection with Birch Pollen Extract Activates B-Cellular Memory Responses in Patients Having Completed Allergen Immunotherapy.
Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- How to Employ Trained Immunity and Trained Immunity-Based Vaccines to Inhibit Allergic Inflammation.Vaccines · 2026Review
- Booster Injection with Birch Pollen Extract Activates B-Cellular Memory Responses in Patients Having Completed Allergen Immunotherapy.European journal of immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Allergen immunotherapy (AIT) of patients with IgE-mediated allergy results in the synthesis of blocking IgG antibodies mediating allergen tolerance. However, as antibody concentrations wane after stopping AIT, tolerance may be lost. The impact of a single booster allergen application on B-cellular memory in AIT-treated birch pollen (BP)-allergic patients was investigated. Twenty-five patients with BP allergy who finished AIT 3-12 years ago received one allergen injection approximately 4 months prior to the next BP season. We determined peripheral Bet v 1-specific IgG-secreting cells (ASC) by ELISPOT analysis and BP-specific IgG, IgG4, and IgE serum antibodies by ImmunoCAP, and the allergen-blocking capacity of IgG/IgG4 antibodies by ELIFAB assay. Clinical responses were assessed by visual analog scales. Immunological findings were compared with the primary B cell response of 12 BP-allergic patients receiving conventional AIT. Bet v 1-specific ASC significantly increased 2-4 weeks after BP-injection, accompanied by enhanced levels of both BP-specific IgG/IgG4 antibodies and allergen-blocking serum activity. Compared with conventional up-dosing, a single booster vaccination led to a markedly stronger B cell response after 4 weeks. Allergen booster injection activates B-cellular memory associated with blocking IgG/IgG4 antibodies, pointing to reinforcement of allergen tolerance after completion of AIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.